Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters

(2023) Ai-ris Y. Collier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera

(2022) Alexander Muik et al.   SCIENCE

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

(2022) Matthew Gagne et al.   CELL

Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection

(2022) Salma Sheikh-Mohamed et al.   Mucosal Immunology

Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines

(2022) Violette Mouro et al.   Mucosal Immunology

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

(2022) Sho Iketani et al.   NATURE

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

(2022) Laith J. Abu-Raddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model

(2022) Stephanie N. Langel et al.   Science Translational Medicine

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

(2022) Hiam Chemaitelly et al.   Nature Communications

Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters

(2022) Peter J. Halfmann et al.   Cell Reports

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

(2022) Kevin K. Ariën et al.   npj Vaccines

Drop the Needle; A Temperature Stable Oral Tablet Vaccine Is Protective against Respiratory Viral Pathogens

(2022) Becca A. Flitter et al.   Vaccines

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

(2022) Aekkachai Tuekprakhon et al.   CELL

Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models

(2022) Alexander A. Cohen et al.   SCIENCE

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants

(2022) Neeltje van Doremalen et al.   Nature Communications

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

(2022) Spyros Chalkias et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection

(2022) Sebastian Havervall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine

(2022) Dapeng Li et al.   Nature Communications

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

(2022) Meera Madhavan et al.   EBioMedicine

Marked Increase in Avidity of SARS-CoV-2 Antibodies 7–8 Months After Infection Is Not Diminished in Old Age

(2021) Daniel Pichler et al.   JOURNAL OF INFECTIOUS DISEASES

Prevention of host-to-host transmission by SARS-CoV-2 vaccines

(2021) Darius Mostaghimi et al.   LANCET INFECTIOUS DISEASES

Immune imprinting and SARS-CoV-2 vaccine design

(2021) Adam K. Wheatley et al.   TRENDS IN IMMUNOLOGY

Oral Vaccination Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Syrian Hamster Challenge Model

(2021) Susan Johnson et al.   JOURNAL OF INFECTIOUS DISEASES

SARS-CoV-2 Subgenomic RNAs: Characterization, Utility, and Perspectives

(2021) Samuel Long   Viruses-Basel

Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study

(2020) David Liebowitz et al.   LANCET INFECTIOUS DISEASES

Enhanced SARS-CoV-2 neutralization by dimeric IgA

(2020) Zijun Wang et al.   Science Translational Medicine

IgA dominates the early neutralizing antibody response to SARS-CoV-2

(2020) Delphine Sterlin et al.   Science Translational Medicine

High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial

(2015) David Liebowitz et al.   LANCET INFECTIOUS DISEASES

Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus

(2015) Tadaki Suzuki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recombinant IgA Is Sufficient To Prevent Influenza Virus Transmission in Guinea Pigs

(2013) C. W. Seibert et al.   JOURNAL OF VIROLOGY

Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans

(2013) Wendy Peters et al.   VACCINE

An Adenovirus-Based Vaccine with a Double-Stranded RNA Adjuvant Protects Mice and Ferrets against H5N1 Avian Influenza in Oral Delivery Models

(2012) Ciaran D. Scallan et al.   Clinical and Vaccine Immunology

Blocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model

(2009) A. C. Lowen et al.   JOURNAL OF VIROLOGY

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans

(2009) Kara L O'Brien et al.   NATURE MEDICINE

Oral adenoviral-based vaccines: historical perspective and future opportunity

(2008) Sean N Tucker et al.   Expert Review of Vaccines